Skip to content

Study · Not a test of the peptide alone · 2025

4 results

Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors Improve Renal Resistive Index in Patients With Type 2 Diabetes: A 26-Week Prospective Observational Real-Life Study.

Vozza A, Volpe S, Custodero C, Colaianni V, Lavarra V, Triggiani D, Crudele L, Bergamasco A, Antonica G, Tortorella C, Piazzolla G

Journal of diabetes research10 Feb 2025Cited by 6 (Europe PMC)

PMID39963363 (opens in a new tab)PMCIDPMC11832268 (opens in a new tab)DOI10.1155/jdr/8182211 (opens in a new tab)PepBankPUB-39963363
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Diabetic kidney disease (DKD) is one of the most life-threatening complications of diabetes and a leading cause of chronic kidney disease. Glucagon-like peptide 1 receptor agonists (GLP1-RAs) or sodium-glucose cotransporter 2 inhibitors (SGLT2is) appear to improve renal outcome in patients with Type 2 diabetes (T2D). In this context, the renal resistive index (RRI) is a useful doppler measure to study DKD and predict its evolution. The aim of this work was to study the effect of treatment with GLP1-RA or SGLT2i on RRI and the relationship between RRI and glycometabolic parameters. One hundred forty-five patients with T2D were enrolled in the study and treated for 26 weeks with once-weekly GLP1-RA (38 patients with dulaglutide and 39 with semaglutide), SGLT2i (40 patients), or other therapies (28 control patients). Clinical, anthropometric, and hematochemical parameters and RRI were measured at baseline (T0) and after 6 months of treatment (T6). Changes at 6 months were studied and compared by treatment group. Patients were predominantly male (58.6%), overweight (93.0%) or frankly obese (60.0%), with hypertension (90.0%) and high (> 0.64) or pathological (> 0.7) RRI values (82.0% or 37.0%, respectively). At baseline, RRI correlated positively with age, fasting blood glucose, glycated hemoglobin (HbA1c), triglycerides, and albuminuria and negatively with estimated-glomerular filtration rate (e-GFR). At T6, patients treated with either GLP1-RA or SGLT2i showed a significant improvement in RRI but not in albuminuria or e-GFR, compared with homologous at baseline. In particular, RRI normalized in 32% and 30% of patients on therapy with GLP1-RA and SGLT2i, respectively, while remaining almost unchanged in controls. Notably, the RRI improvement was independent of age, gender, diabetes duration, and changes in BMI, waist circumference, HbA1c, and e-GFR. In conclusion, RRI can be used to detect early kidney damage and follow the evolution of DKD. GLP1-RA and SGLT2i improve RRI, demonstrating benefits on cardiovascular risk and renal outcomes.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, treatment with pooled GLP1-RA (dulaglutide and semaglutide) or SGLT2i improved the renal resistive index over 26 weeks versus baseline.

    In plain wordsIn adults with type 2 diabetes, kidney blood-flow resistance improved after 6 months on GLP-1 drugs or SGLT2 inhibitors, compared with baseline.

    Peptide
    Semaglutide
    Outcome
    DecreaseRenal resistive index at 6 months
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    At T6, patients treated with either GLP1-RA or SGLT2i showed a significant improvement in RRI but not in albuminuria or e-GFR, compared with homologous at baseline
    2 context sentences
    Summary · context
    One hundred forty-five patients with T2D were enrolled in the study and treated for 26 weeks with once-weekly GLP1-RA (38 patients with dulaglutide and 39 with semaglutide), SGLT2i (40 patients), or other therapies (28 control patients).
    Summary · context
    Clinical, anthropometric, and hematochemical parameters and RRI were measured at baseline (T0) and after 6 months of treatment (T6).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, pooled GLP1-RA or SGLT2i treatment did not significantly improve albuminuria or e-GFR over 26 weeks.

    In plain wordsIn adults with type 2 diabetes, 6 months of GLP-1 drugs or SGLT2 inhibitors did not clearly change albuminuria or kidney filtration rate.

    Peptide
    Semaglutide
    Outcome
    No significant changeAlbuminuria and e-GFR at 6 months
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    but not in albuminuria or e-GFR, compared with homologous at baseline
    2 context sentences
    Summary · context
    One hundred forty-five patients with T2D were enrolled in the study and treated for 26 weeks with once-weekly GLP1-RA (38 patients with dulaglutide and 39 with semaglutide), SGLT2i (40 patients), or other therapies (28 control patients).
    Summary · context
    Clinical, anthropometric, and hematochemical parameters and RRI were measured at baseline (T0) and after 6 months of treatment (T6).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, renal resistive index normalized in 32% of patients on GLP1-RA (dulaglutide or semaglutide) and 30% on SGLT2i, but stayed almost unchanged in controls.

    In plain wordsIn adults with type 2 diabetes, kidney blood-flow resistance normalized in 32% on GLP-1 drugs and 30% on SGLT2 inhibitors, not in controls.

    Peptide
    Semaglutide
    Outcome
    Not applicableNormalization of renal resistive index
    Study

    n: not reported in source

    Comparator
    Controls on other therapies
    Outcome group
    Kidney function · Kidney and urinary

    Measurements

    RRI normalized
    32%
    GLP1-RA
    RRI normalized
    30%
    SGLT2i

    Source sentences

    Summary
    In particular, RRI normalized in 32% and 30% of patients on therapy with GLP1-RA and SGLT2i, respectively, while remaining almost unchanged in controls.
    2 context sentences
    Summary · context
    One hundred forty-five patients with T2D were enrolled in the study and treated for 26 weeks with once-weekly GLP1-RA (38 patients with dulaglutide and 39 with semaglutide), SGLT2i (40 patients), or other therapies (28 control patients).
    Summary · context
    Clinical, anthropometric, and hematochemical parameters and RRI were measured at baseline (T0) and after 6 months of treatment (T6).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, the renal resistive index improvement was independent of age, gender, diabetes duration, and changes in BMI, waist circumference, HbA1c and e-GFR.

    In plain wordsIn adults with type 2 diabetes, the kidney blood-flow improvement did not depend on age, sex, diabetes duration or changes in weight or HbA1c.

    Peptide
    Semaglutide
    Outcome
    Not applicableIndependence of RRI improvement from covariates
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    Notably, the RRI improvement was independent of age, gender, diabetes duration, and changes in BMI, waist circumference, HbA1c, and e-GFR.
    2 context sentences
    Summary · context
    One hundred forty-five patients with T2D were enrolled in the study and treated for 26 weeks with once-weekly GLP1-RA (38 patients with dulaglutide and 39 with semaglutide), SGLT2i (40 patients), or other therapies (28 control patients).
    Summary · context
    Clinical, anthropometric, and hematochemical parameters and RRI were measured at baseline (T0) and after 6 months of treatment (T6).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.